Shire slaps US rival with a lawsuit
Drugs firm Shire has filed a lawsuit against US rival Watson Pharmaceuticals, claiming an infringement of Shire's ADDERALL XR patents, and a breach of contract.
The lawsuit results from an Abbreviated New Drug Application (ANDA) recently filed by Watson in which it indicated it would sell generic versions of ADDERALL XR before the expiration of Shire's patents.
Under the terms of the US Hatch-Waxman Act, a piece of legislation dealing with generic drugs and pharmaceuticals patents, there will be up to a 30-month stay with respect to Watson's proposed generic products.
The lawsuit also alleges that Watson has violated existing settlement and licence agreements between Shire and Watson, signed in November 2007, arising from an ANDA that Watson filed in 2006, which also sought approval to market generic versions of ADDERALL XR.